Grant: Master's Award: Canada Graduate Scholarships
University of Manitoba
$17,500.00
Intravenous immune globulin (IVIG) in severe sepsis and septic shock
EF 2015-16
Résumé
Intravenous Immune Globulin (IVIG) in Severe Sepsis and Septic ShockThis program of research will examine the impact of IVIG in severe sepsis and septic shock. Sepsis is the third leading causes of death for critically ill patients worldwide. Despite advances in the early identification and treatment of sepsis, mortality remains 20-40% in developed countries. The development of new antimicrobials has slowed and antimicrobial resistance continues to emerge worldwide. The development and evaluation of adjunctive therapies in sepsis is more important now than ever. Meta-analyses have supported a mortality benefit of IVIG as an adjunctive therapy in patients with severe sepsis and septic shock but clinical use remains low.My research will establish current views of intensivists on the balance of efficacy versus harm of IVIG in patients with severe sepsis and septic shock, describe current utilization patterns, identify facilitators and barriers of use and obtain a consensus on the need for further clinical study through a mixed-mode international survey. An economic modelling experiment will evaluate the economic impact of adoption of this therapy in heterogeneous global intensive care settings. This work will inform a proposal for a clinical trial of IVIG plus standard therapy versus standard therapy alone for the treatment of severe sepsis and septic shock.The results of this clinical research will inform the treatment of one of the commonest and greatest threats to human health worldwide. Adequate evidence supporting the efficacy of IVIG in severe sepsis and septic shock will change the standard of care for this ubiquitous disease process.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Manitoba, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
349824
Name
Leeies Murdoch A
Region
Manitoba
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Intravenous immune globulin (IVIG) in severe sepsis and septic shock
Programtype2
Studentship Programs
Orgnameinp2
University of Manitoba
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adjunctive Therapy; Critical Care; Economic Evaluation; Immunomodulation; Intravenous Immune Globulin; Multi-Organ Dysfunction Syndrome; Resuscitation; Sepsis; Septic Shock; Severe Sepsis
Abstract
Intravenous Immune Globulin (IVIG) in Severe Sepsis and Septic ShockThis program of research will examine the impact of IVIG in severe sepsis and septic shock. Sepsis is the third leading causes of death for critically ill patients worldwide. Despite advances in the early identification and treatment of sepsis, mortality remains 20-40% in developed countries. The development of new antimicrobials has slowed and antimicrobial resistance continues to emerge worldwide. The development and evaluation of adjunctive therapies in sepsis is more important now than ever. Meta-analyses have supported a mortality benefit of IVIG as an adjunctive therapy in patients with severe sepsis and septic shock but clinical use remains low.My research will establish current views of intensivists on the balance of efficacy versus harm of IVIG in patients with severe sepsis and septic shock, describe current utilization patterns, identify facilitators and barriers of use and obtain a consensus on the need for further clinical study through a mixed-mode international survey. An economic modelling experiment will evaluate the economic impact of adoption of this therapy in heterogeneous global intensive care settings. This work will inform a proposal for a clinical trial of IVIG plus standard therapy versus standard therapy alone for the treatment of severe sepsis and septic shock.The results of this clinical research will inform the treatment of one of the commonest and greatest threats to human health worldwide. Adequate evidence supporting the efficacy of IVIG in severe sepsis and septic shock will change the standard of care for this ubiquitous disease process.
Competitiondate
201512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Leeies, Murdoch A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~